A Phase 1 Study for the Evaluation of Excretion (Mass Balance) and Pharmacokinetics of 14C-Labeled Belinostat in Patients With Advanced Cancer
Latest Information Update: 07 Oct 2022
At a glance
- Drugs Belinostat (Primary)
- Indications Cancer
- Focus Pharmacokinetics
- Sponsors Spectrum Pharmaceuticals
- 14 Jan 2016 Status changed from active, no longer recruiting to completed, as per an article published in the Investigational New Drugs
- 14 Jan 2016 Results published in the Investigational New Drugs
- 10 Mar 2015 Planned End Date changed from 1 Apr 2014 to 1 Dec 2015 as reported by ClinicalTrials.gov record.